May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Validity and Reliability of the German Version of the 25–item National Eye Institute Visual Function Questionnaire in Patients with Age–related Macular Degeneration
Author Affiliations & Notes
  • S.P. Lustig
    Global Research & Development, Pfizer Inc, Groton, CT
  • J.C. Cappelleri
    Global Research & Development, Pfizer Inc, Groton, CT
  • J.A. Chisholm
    Global Research & Development, Pfizer Inc, New London, CT
  • C.A. Getter
    Global Research & Development, Pfizer Inc, Groton, CT
  • A.M. Pleil
    Global Research & Development, Pfizer Inc, San Diego, CA
  • M.B. Reichel
    Augenabteilung Klinikum Konstanz, Konstanz, Germany
  • Footnotes
    Commercial Relationships  S.P. Lustig, Pfizer Inc E; J.C. Cappelleri, Pfizer Inc E; J.A. Chisholm, Pfizer Inc E; C.A. Getter, Pfizer Inc E; A.M. Pleil, Pfizer Inc E; M.B. Reichel, Pfizer Inc C.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1373. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.P. Lustig, J.C. Cappelleri, J.A. Chisholm, C.A. Getter, A.M. Pleil, M.B. Reichel; Validity and Reliability of the German Version of the 25–item National Eye Institute Visual Function Questionnaire in Patients with Age–related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1373.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: We investigated the measurement properties of the German version of the 25–item National Eye Institute Visual Function Questionnaire (NEI VFQ–25) in patients with age–related macular degeneration (AMD). Methods: This cross–sectional study included 187 patients who attended a clinic in Germany. Patients belonged to 1 of 3 severity classes: 1) early AMD in both eyes (n=35); 2) late stage AMD in 1 eye and early stage AMD in the other eye (n=111); and 3) late stage AMD in both eyes (n=41). Correlations of scores were calculated between NEI VFQ–25 and Snellen visual acuity. Mean scores on the NEI VFQ–25 were compared for different stages of severity using linear regression adjusting for age, gender, and number of comorbidities. Cronbach’s alpha was used for internal consistency reliability, and an intraclass correlation coefficient was used for test–retest (2 weeks apart) reliability. Results: For the better eye, visual acuity correlated strongly and significantly (P<0.0001) with NEI VFQ–25 domains on General Vision (r=0.63), Near Vision (r=0.70), Distance Vision (r=0.69), Driving (r=0.67), and with the Composite Score (r=0.66). Visual acuity correlated moderately and significantly with Peripheral Vision (r=0.44), Role Limitation (r=0.39), Dependency (r=0.55), Social Functioning (r=0.56), and Mental Health (r=0.44). For the worse eye, visual acuity scores were generally lower and remained moderate for most components. Discriminate validity was evidenced with significant differences (P<0.05) in mean scores among severity levels of AMD for most NEI VFQ–25 components. Cronbach’s alpha and intraclass correlations exceeded 0.70 on most components. Conclusion: The German version of the NEI VFQ–25 has demonstrated reliability and validity as a measure of vision–related quality of life in patients with AMD.

Keywords: age–related macular degeneration • quality of life • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×